Vaccin vivant combiné contre le coryza des chats, causé par FHV-1, FCV et Chlamydophila felis, ainsi que contre la panleucopénie féline
3 ans de protection contre la panleucopénie féline, après une immunisation de base effectuée à l’âge de 8 et de 12 semaines, démontrée par des inoculations d’épreuve18
1 an de protection contre les deux germes principaux du coryza des chats, le virus herpès félin et le calicivirus félin
1 an de protection contre Chlamydophila felis
Immunisation précoce possible dès l’âge de 6 semaines
La souche Baker atténuée de Chlamydophila felis contenue dans Nobivac®, un vaccin vivant, garantit une meilleure protection vaccinale que les vaccins inactivés19
Chlamydophila felis a été isolée chez 30% des chats souffrant d’une conjonctivite et est présente dans de nombreux ménages hébergeant plusieurs chats, comme dans beaucoup de pensions pour chats20
Contient la souche F9 du calicivirus qui présente une forte neutralisation croisée avec la souche sauvage actuelle 255 et garantit ainsi une large protection17
Sans adjuvant, donc particulièrement bien toléré par les tissus
Nobivac® FORCAT est parfaitement bien toléré: une étude montre que 99.7% des 1’263 chats vaccinés avec Nobivac® FORCAT n’ont présenté aucune réaction indésirable à la vaccination1
Data on file, reprint available on request at: MSD Animal Health GmbH, Weystrasse 20, 6006 Luzern
Bergmann J.G.H.E.(1997): Comparative study with 5 different distemper vaccines. Veterinary Quarterly 19, 51
Hoskins et al (1995): Challenge trial of a new attenuated canine parvovirus vaccine. J Vet Int Med, 9, 197
Larson (2008): Do two canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther 5, 94-101
Spibey et al (2008): Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 128, 48-55
Institut für Viruskrankheiten und Immunprophylaxe (2010): Impfung von Katzen- und Marderartigen, Waschbären, Elefanten und Neuweltkameliden
Barmettler R et al (2011): Assessment of exposure to Leptospira serovars in veterinary staff and dog owners in contact with infected dogs. JAVMA 238, 183-188
Klaasen et al (2013). A novel tetravalent Leptospira vacterin protects against infection and shedding following challenge in dogs. Vet Rec 172, 181
Ellis WA (2010): Control of canine leptospirosis in Europe: time for a change? Vet Rec 167, 602-605
Gore et al (2005): Three year duration of immunology in dogs following vaccination against canine adenovirus type-1, canine parvovirus and canine distemper virus. Vet Ther 6, 5-14
Abdelmagid et al (2004): Evaluation of the Duration of Immunity of a Canine Combination Vaccine against Virulent Parvovirus, Infectious Canine Hepatitis Virus, and Distemper Virus Experimental Challenges. Vet Ther 5, No 3, Fall 2004
Brunner R. (1991): Immunkompetenz und Impfungen beim Hundewelpen. Collegium Veterinarium XXII, 102-109
Hoskins J.D. et al (1995): Performance of a new generation canine parvovirus in Rottweiler puppies. Canine practice 22: 29-31
Ohmori K et al (2007): Immunoblot analysis for IgE-reactive components of fetal calf serum in dogs that developed allergic reactions after non-rabies vaccination. Vet Imm 115: 166-171
Gore T, Headley M, Raris R, et al (2005) Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Veterinary Record 156, 482-483
Jacobs AA, Theleen RP, Jaspers R, et al (2005): Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Veterinary Record 157, 19-23
Porter, C.J. et al (2008): Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates. Journal of Feline Medicine and Surgery (2008) 10, 32-40
Gore et al (2006): Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus and feline panleukopenia virus. Vet Ther, 7 (3), 213-222
Brunner C. et al (2006): Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with chlamydial component. Vaccine, 24, 1838-1846
Wills JM et al (1988): Prevalence of Chlamydophilapsittaci in different cat populations in Britain. JSAP, 327-339
Hu et al (2006): Prevention of rabies virus infection in dog by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes and Infection 8, 1090-7
Van de Zande et al (2009): Comments to ‘Comparison of antibody responses after vaccination with two inactivated rabies vaccines’. Vet Microbiol. 2009 Mar 4
WHO Technical Report Series, No. 840, 1994, Annex 6
Data on file. Intervet subject memo report 03R/0384: analysis of rabies serology data from UK
Score clinique
Score clinique des chats vaccinés avec Nobivac® et des chats témoins non vaccinés après inoculation d’épreuve avec A) FPLV, B) FHV et C) FCV1
Data on file, reprint available on request at: MSD Animal Health GmbH, Weystrasse 20, 6006 Luzern
Bergmann J.G.H.E.(1997): Comparative study with 5 different distemper vaccines. Veterinary Quarterly 19, 51
Hoskins et al (1995): Challenge trial of a new attenuated canine parvovirus vaccine. J Vet Int Med, 9, 197
Larson (2008): Do two canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther 5, 94-101
Spibey et al (2008): Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 128, 48-55
Institut für Viruskrankheiten und Immunprophylaxe (2010): Impfung von Katzen- und Marderartigen, Waschbären, Elefanten und Neuweltkameliden
Barmettler R et al (2011): Assessment of exposure to Leptospira serovars in veterinary staff and dog owners in contact with infected dogs. JAVMA 238, 183-188
Klaasen et al (2013). A novel tetravalent Leptospira vacterin protects against infection and shedding following challenge in dogs. Vet Rec 172, 181
Ellis WA (2010): Control of canine leptospirosis in Europe: time for a change? Vet Rec 167, 602-605
Gore et al (2005): Three year duration of immunology in dogs following vaccination against canine adenovirus type-1, canine parvovirus and canine distemper virus. Vet Ther 6, 5-14
Abdelmagid et al (2004): Evaluation of the Duration of Immunity of a Canine Combination Vaccine against Virulent Parvovirus, Infectious Canine Hepatitis Virus, and Distemper Virus Experimental Challenges. Vet Ther 5, No 3, Fall 2004
Brunner R. (1991): Immunkompetenz und Impfungen beim Hundewelpen. Collegium Veterinarium XXII, 102-109
Hoskins J.D. et al (1995): Performance of a new generation canine parvovirus in Rottweiler puppies. Canine practice 22: 29-31
Ohmori K et al (2007): Immunoblot analysis for IgE-reactive components of fetal calf serum in dogs that developed allergic reactions after non-rabies vaccination. Vet Imm 115: 166-171
Gore T, Headley M, Raris R, et al (2005) Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Veterinary Record 156, 482-483
Jacobs AA, Theleen RP, Jaspers R, et al (2005): Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Veterinary Record 157, 19-23
Porter, C.J. et al (2008): Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates. Journal of Feline Medicine and Surgery (2008) 10, 32-40
Gore et al (2006): Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus and feline panleukopenia virus. Vet Ther, 7 (3), 213-222
Brunner C. et al (2006): Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with chlamydial component. Vaccine, 24, 1838-1846
Wills JM et al (1988): Prevalence of Chlamydophilapsittaci in different cat populations in Britain. JSAP, 327-339
Hu et al (2006): Prevention of rabies virus infection in dog by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes and Infection 8, 1090-7
Van de Zande et al (2009): Comments to ‘Comparison of antibody responses after vaccination with two inactivated rabies vaccines’. Vet Microbiol. 2009 Mar 4